MILLIONS of Filipinos stand to benefit from the promising results of Covovax, licensed by Novavax, following the global announcement of final efficacy analysis of the United Kingdom (UK) Phase 3 trials of the said vaccine on Tuesday (Philippine time).
Philippine Covovax distributor Faberco Life Sciences, citing the results released by Novavax in the United States today said the vaccine provides 100-percent protection against severe cases of Covid-19 and 96.4-percent efficacy against the original strain of Covid-19.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.